You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

mantle cell lymphoma (MCL)

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma Trial in Houston (Biospecimen Collection, Follow-Up)

Recruiting
  • Recurrent Mantle Cell Lymphoma
  • Refractory Mantle Cell Lymphoma
  • Biospecimen Collection
  • Follow-Up
  • Houston, Texas
    M D Anderson Cancer Center
Dec 5, 2022

Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma Trial in New York (Ibrutinib, Pembrolizumab)

Recruiting
  • Chronic Lymphocytic Leukemia
  • Mantle Cell Lymphoma
  • New York, New York
    Icahn School of Medicine at Mount Sinai
Aug 22, 2022

Mantle Cell Lymphoma Trial in Houston (Ibrutinib)

Recruiting
  • Mantle Cell Lymphoma
  • Houston, Texas
    M D Anderson Cancer Center
Nov 1, 2022

Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma (MCL), Relapsed Mantle Cell Lymphoma Trial (BGB-11417)

Not yet recruiting
  • Mantle Cell Lymphoma
  • +2 more
  • (no location specified)
Jul 25, 2022

Chronic Lymphocytic Leukemia (CLL), Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL) Trial (Routine care as per

Not yet recruiting
  • Chronic Lymphocytic Leukemia (CLL)
  • +5 more
  • Routine care as per site standard.
  • (no location specified)
Sep 15, 2023

Blastoid Variant Mantle Cell Lymphoma, CCND1 Protein Overexpression, CD20 Positive Trial in Houston (Acalabrutinib, Venetoclax)

Recruiting
  • Blastoid Variant Mantle Cell Lymphoma
  • +8 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 5, 2022

Relapsed or Refractory B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL) Trial in Beijing

Recruiting
  • Relapsed or Refractory B-cell Lymphoma
  • +6 more
  • Beijing, China
    Beijing Cancer Hospital
Feb 6, 2023

Mantle Cell Lymphoma Trial in Busan (Ixazomib)

Recruiting
  • Mantle Cell Lymphoma
  • Busan, Western, Korea, Republic of
    Kosin University Gospel Hospital
Mar 31, 2022

Mantle Cell Lymphoma (MCL) Trial in Australia, Canada, United States (Acalabrutinib, Venetoclax, Rituximab)

Not yet recruiting
  • Mantle Cell Lymphoma (MCL)
  • Duarte, California
  • +11 more
Jul 17, 2023

Mantle Cell Lymphoma, Newly-diagnosed Mantle Cell Lymphoma Trial in Guangzhou (Zanubrutinib and Rituximab, R-DHAOx, Zanubrutinib

Recruiting
  • Mantle Cell Lymphoma
  • Newly-diagnosed Mantle Cell Lymphoma
  • Zanubrutinib and Rituximab
  • +2 more
  • Guangzhou, Guangdong, China
  • +2 more
May 6, 2022

Aggressive B-Cell Non-Hodgkin's Lymphoma, Aggressive B-Cell NHL, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Trial

Not yet recruiting
  • Aggressive B-Cell Non-Hodgkin's Lymphoma
  • +4 more
  • (no location specified)
Dec 16, 2022

Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma Trial in Houston (Eprenetapopt, Venetoclax)

Withdrawn
  • Recurrent Mantle Cell Lymphoma
  • Refractory Mantle Cell Lymphoma
  • Houston, Texas
    M D Anderson Cancer Center
Feb 23, 2022

Mantle Cell Lymphoma Trial in Duarte (Acalabrutinib, Ublituximab, Umbralisib)

Suspended
  • Mantle Cell Lymphoma
  • Duarte, California
    City of Hope Medical Center
Jun 7, 2022

Rituximab, Lenalidomide, Zebutinib ,Mantle Cell Lymphoma Trial in Hangzhou (ZR2 RDHAP)

Recruiting
  • Rituximab, Lenalidomide, Zebutinib ，Mantle Cell Lymphoma
  • ZR2 RDHAP
  • Hangzhou, Zhejiang, China
    Zhejiang Cancer Hospital
Aug 8, 2023

Non-Hodgkin's Lymphoma (NHL), Activated B-Cell Type DLBCL (ABC-DLBCL), Mantle Cell Lymphoma (MCL) Trial in Indianapolis, Spokane

Recruiting
  • Non-Hodgkin's Lymphoma (NHL)
  • +4 more
  • Indianapolis, Indiana
  • +1 more
Jul 12, 2022

Mantle Cell Lymphoma Trial in Birmingham (Ublituximab, Umbralisib)

Recruiting
  • Mantle Cell Lymphoma
  • Birmingham, Alabama
    University of Alabama at Birmingham
Sep 8, 2021

Mantle Cell Lymphoma Trial in Hackensack (Lenalidomide, Ibrutinib, Rituximab)

Active, not recruiting
  • Mantle Cell Lymphoma
  • Hackensack, New Jersey
    The Cancer Center at Hackensack University Medical Center
May 3, 2022

Mantle Cell Lymphoma Trial in Beijing (DTRMWXHS-12)

Active, not recruiting
  • Mantle Cell Lymphoma
  • Beijing, China
    Peking University Cancer Hospital
Aug 18, 2021

Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma Trial in Duarte (Acalabrutinib,

Recruiting
  • Recurrent Mantle Cell Lymphoma
  • Refractory Mantle Cell Lymphoma
  • Acalabrutinib
  • CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes
  • Duarte, California
    City of Hope Comprehensive Cancer Center
Jun 16, 2022

Mantle Cell Lymphoma, Refractory Lymphoma Trial in Boston (Acalabrutinib, Venetoclax, Obinutuzumab)

Recruiting
  • Mantle Cell Lymphoma
  • Refractory Lymphoma
  • Boston, Massachusetts
  • +1 more
Aug 8, 2022

Mantle Cell Lymphoma Trial in China (400mg of TQB3909 tablets, 600mg of TQB3909 tablets)

Recruiting
  • Mantle Cell Lymphoma
  • 400mg of TQB3909 tablets
  • 600mg of TQB3909 tablets
  • Beijing, Beijing, China
  • +27 more
Oct 26, 2023

Ibrutinib Combined With Bendamustine and Rituximab in Newly

Recruiting
  • Mantle Cell Lymphoma (MCL)
    • Beijing, Beijing, China
      Peking University Third Hospital
    May 31, 2022

    Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Diffuse Large B Cell Lymphoma (DLBCL) Trial in Manchester,

    Recruiting
    • Chronic Lymphocytic Leukemia (CLL)
    • +7 more
    • Manchester, United Kingdom
    • +2 more
    Aug 11, 2022

    Non Hodgkin Lymphoma (NHL), Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL) Trial in Milwaukee (8/12-Day

    Recruiting
    • Non Hodgkin Lymphoma (NHL)
    • +6 more
    • 8/12-Day Production of Car-T Cells
    • +2 more
    • Milwaukee, Wisconsin
      Medical College of Wisconsin and Froedtert Hospital
    Jul 1, 2022

    Lymphoma, Mantle-Cell, Recurrent Lymphoma, Mantle-Cell Trial in United States (ABT-199 and Ibrutinib Combination)

    Completed
    • Lymphoma, Mantle-Cell
    • Recurrent Lymphoma, Mantle-Cell
    • ABT-199 and Ibrutinib Combination
    • Duarte, California
    • +3 more
    May 22, 2022